Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Sponsor: Kyowa Kirin Co., Ltd.
Listed as NCT02312687, this PHASE2 trial focuses on X-Linked Hypophosphatemia and remains completed. Sponsored by Kyowa Kirin Co., Ltd., it has been updated 15 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE2
-
May 2023 — Jun 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2023 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2019 — Jan 2020 [monthly]
Completed PHASE2
-
Apr 2019 — Aug 2019 [monthly]
Completed PHASE2
-
Jan 2019 — Apr 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin Co., Ltd.
- Kyowa Kirin, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .